Inflamax   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Mississauga Canada (2012)
Status: Acquired by Cliantha Research Limited (2017)

Organization Overview

First Clinical Trial
2013
NCT01919554
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Inflamax Research | Inflamax Research Limited | Inflamax Research Ltd. | Inflamax Researc Incorporated

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Hypersensitivity (Phase 2)

Hypersensitivity, Immediate (Phase 1)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 11